Martin Charles Faulkes is Director at VOLITIONRX LTD (VNRX). They have made 8 open-market trades across 1 company since 2014, most recently 2024-01-24.
CIK 0001577872
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $1.3M since 2014, against 1 sale. Across 7 scored buys the stock is up 8.8% at ninety days, and 5.1 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| VNRX | 1,740,207 | $316K |
Shares reported on the most recent Form 4, priced at the 2024-01-26 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 57% | 71% | 71% |
| Avg Move | -0.4% | +5.9% | +8.8% |
| Alpha | -0.1% | +4.4% | +5.1% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VNRX | BUY | 2023-08-31 | 2023-09-01 | $1.28 | $12K | -6.2% | -41.9% | -41.2% |
| VNRX | BUY | 2022-12-16 | 2022-12-19 | $2.10 | $116K | +8.5% | +16.1% | -26.3% |
| VNRX | SELL | 2020-09-09 | 2020-09-10 | $3.21 | $209K | -7.3% | +14.5% | +6.9% |
| VNRX | BUY | 2019-08-27 | 2019-08-28 | $3.75 | $38K | +0.8% | +45.2% | +40.4% |
| VNRX | BUY | 2019-08-15 | 2019-08-16 | $3.94 | $197K | -9.8% | -3.4% | +31.0% |
| VNRX | BUY | 2019-06-11 | 2019-06-13 | $3.10 | $461K | +5.7% | +12.4% | +31.1% |
| VNRX | BUY | 2019-06-10 | 2019-06-12 | $3.02 | $427K | +3.0% | +10.5% | +24.3% |
| VNRX | BUY | 2014-09-15 | 2014-09-17 | $2.16 | $11K | -4.5% | +2.1% | +2.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.